摘要
目的:运用磷脂酰肌醇3-激酶抑制剂(phosphatidylinositol3-kinase,PI3-K)LY294002[2-(4-吗啉基)-8-苯基-4氢-1-苯并吡喃-4-酮]作用于胆管癌细胞系QBC939,探讨抑制PI3K/AKT信号转导通路对胆管癌化疗的增敏作用。方法:MTT法检测单独使用5-FU,MMC,celecoxib,联合磷酸化抑制剂LY294002,体外对胆管癌细胞系QBC939的抑制作用;运用流式细胞技术检测QBC939凋亡抑制率。结果:运用LY294002后能明显增加5-FU,MMC,celecoxib对胆管癌细胞系QBC939体外培养细胞的抑制作用,并且能提高其凋亡率。结论:LY294002能有效提高化疗药物5-FU,MMC,celecoxib体外对QBC939细胞抑制作用的敏感性;抑制PI3K介导的信号转导通路对胆管癌肿瘤的治疗中可能有一定的协同作用。
Objective： To explore the specific inhibitor LY294002 of the signaling pathway PI3K/ AKT that increases sensitivity to the regular chemotherapeutic agent of cholangiocarcinoma. Methods： The inhibition of cholangiocarcinoma was detected when treated individually with 5-FU, MMC, or celecoxib, and was compared to a combination of those drugs individually with LY294002. Under the same conditions, the apoptosis ratio was detected using flow cytometry. Results： The phosphorylation inhibitor LY294002 can increase sensitivity to 5-FU and MMC and also increase the apoptosis ratio in vitro. Conclusion： The phosphorylation inhibitor LY294002 can significantly enhance sensitivity to the chemotherapeutic agent. Inhibition of the PI3K/AKT on treatment of cholangiocarcinoma. signaling pathway could have a synergistic effect on treatment of cholangiocarcinoma.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2006年第11期611-613,共3页
Chinese Journal of Clinical Oncology
基金
国家863课题重大基金资助(编号:2002AA214061)
